This executive summary will explore the benchmark practices for rapid progression from first–in–human to large–scale commercial manufacture for microdosing API. Xcelodose®–based systems are an industry standard for rapid and accurate microdosing and an integral part of accelerated pathways to first–in–human studies. Utilization of the Xcelodose® technology can increase speed to clinic and quickly assess new compounds while remaining cost–conscious. Upon successful clinical studies, scale up to large–scale manufacture has previously been a limitation. Read the executive summary to learn more.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center